These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 20930314

  • 1. CERAD neuropsychological battery total score in multinational mild cognitive impairment and control populations: the AddNeuroMed study.
    Paajanen T, Hänninen T, Tunnard C, Mecocci P, Sobow T, Tsolaki M, Vellas B, Lovestone S, Soininen H, Addneuromed Consortium.
    J Alzheimers Dis; 2010; 22(4):1089-97. PubMed ID: 20930314
    [Abstract] [Full Text] [Related]

  • 2. A total score for the CERAD neuropsychological battery.
    Chandler MJ, Lacritz LH, Hynan LS, Barnard HD, Allen G, Deschner M, Weiner MF, Cullum CM.
    Neurology; 2005 Jul 12; 65(1):102-6. PubMed ID: 16009893
    [Abstract] [Full Text] [Related]

  • 3. CERAD test performances in amnestic mild cognitive impairment and Alzheimer's disease.
    Karrasch M, Sinervä E, Grönholm P, Rinne J, Laine M.
    Acta Neurol Scand; 2005 Mar 12; 111(3):172-9. PubMed ID: 15691286
    [Abstract] [Full Text] [Related]

  • 4. CERAD neuropsychological compound scores are accurate in detecting prodromal alzheimer's disease: a prospective AddNeuroMed study.
    Paajanen T, Hänninen T, Tunnard C, Hallikainen M, Mecocci P, Sobow T, Tsolaki M, Vellas B, Lovestone S, Soininen H.
    J Alzheimers Dis; 2014 Mar 12; 39(3):679-90. PubMed ID: 24246420
    [Abstract] [Full Text] [Related]

  • 5. [Validation of the Short Cognitive Battery (B2C). Value in screening for Alzheimer's disease and depressive disorders in psychiatric practice].
    Robert PH, Schuck S, Dubois B, Lépine JP, Gallarda T, Olié JP, Goni S, Troy S.
    Encephale; 2003 Mar 12; 29(3 Pt 1):266-72. PubMed ID: 12876552
    [Abstract] [Full Text] [Related]

  • 6. Validation of the German revised Addenbrooke's cognitive examination for detecting mild cognitive impairment, mild dementia in alzheimer's disease and frontotemporal lobar degeneration.
    Alexopoulos P, Ebert A, Richter-Schmidinger T, Schöll E, Natale B, Aguilar CA, Gourzis P, Weih M, Perneczky R, Diehl-Schmid J, Kneib T, Förstl H, Kurz A, Danek A, Kornhuber J.
    Dement Geriatr Cogn Disord; 2010 Mar 12; 29(5):448-56. PubMed ID: 20502019
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Differentiation between mild cognitive impairment, Alzheimer's disease and depression by means of cued recall.
    Dierckx E, Engelborghs S, De Raedt R, De Deyn PP, Ponjaert-Kristoffersen I.
    Psychol Med; 2007 May 12; 37(5):747-55. PubMed ID: 17164030
    [Abstract] [Full Text] [Related]

  • 11. Detecting prodromal Alzheimer's disease in mild cognitive impairment: utility of the CAMCOG and other neuropsychological predictors.
    Gallagher D, Mhaolain AN, Coen R, Walsh C, Kilroy D, Belinski K, Bruce I, Coakley D, Walsh JB, Cunningham C, Lawlor BA.
    Int J Geriatr Psychiatry; 2010 Dec 12; 25(12):1280-7. PubMed ID: 21086538
    [Abstract] [Full Text] [Related]

  • 12. [Mild cognitive impairment and Alzheimer's disease: an investigation of the CERAD-NP test battery].
    Barth S, Schönknecht P, Pantel J, Schröder J.
    Fortschr Neurol Psychiatr; 2005 Oct 12; 73(10):568-76. PubMed ID: 16217697
    [Abstract] [Full Text] [Related]

  • 13. Screening for amnestic mild cognitive impairment and early Alzheimer's disease with M@T (Memory Alteration Test) in the primary care population.
    Rami L, Molinuevo JL, Sanchez-Valle R, Bosch B, Villar A.
    Int J Geriatr Psychiatry; 2007 Apr 12; 22(4):294-304. PubMed ID: 16998781
    [Abstract] [Full Text] [Related]

  • 14. Differentiation between mild cognitive impairment and Alzheimer's disease using the FMLL mini-battery.
    Abizanda P, López-Ramos B, Romero L, Sánchez-Jurado PM, León M, Martín-Sebastiá E, López-Jiménez E.
    Dement Geriatr Cogn Disord; 2009 Apr 12; 28(2):179-86. PubMed ID: 19713701
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Quantitative EEG in progressing vs stable mild cognitive impairment (MCI): results of a 1-year follow-up study.
    Luckhaus C, Grass-Kapanke B, Blaeser I, Ihl R, Supprian T, Winterer G, Zielasek J, Brinkmeyer J.
    Int J Geriatr Psychiatry; 2008 Nov 12; 23(11):1148-55. PubMed ID: 18537220
    [Abstract] [Full Text] [Related]

  • 18. Combination analysis of neuropsychological tests and structural MRI measures in differentiating AD, MCI and control groups--the AddNeuroMed study.
    Liu Y, Paajanen T, Zhang Y, Westman E, Wahlund LO, Simmons A, Tunnard C, Sobow T, Mecocci P, Tsolaki M, Vellas B, Muehlboeck S, Evans A, Spenger C, Lovestone S, Soininen H, AddNeuroMed Consortium.
    Neurobiol Aging; 2011 Jul 12; 32(7):1198-206. PubMed ID: 19683363
    [Abstract] [Full Text] [Related]

  • 19. Cross validation of the Montreal Cognitive Assessment in community dwelling older adults residing in the Southeastern US.
    Luis CA, Keegan AP, Mullan M.
    Int J Geriatr Psychiatry; 2009 Feb 12; 24(2):197-201. PubMed ID: 18850670
    [Abstract] [Full Text] [Related]

  • 20. Diagnostic accuracy of CERAD total score in a Colombian cohort with mild cognitive impairment and Alzheimer's disease affected by E280A mutation on presenilin-1 gene.
    Aguirre-Acevedo DC, Jaimes-Barragán F, Henao E, Tirado V, Muñoz C, Reiman EM, Tariot PN, Langbaum JB, Lopera F.
    Int Psychogeriatr; 2016 Mar 12; 28(3):503-10. PubMed ID: 26478578
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.